EGFR and neoplasm: Similarly, a study with panitumumab-IRDye800CW found EGFR expression did not directly correlate with the tumor-to-background fluorescent signal ratio, due to factors like tumor vascularity and probe penetration affecting fluorescence beyond receptor levels [38].